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Abstract
Background: Schizophrenia is a severe disabling brain disease affecting about 1% of the population. Individual microRNAs
(miRNAs) affect moderate downregulation of gene expression. In addition, components required for miRNA processing and/
or function have also been implicated in X-linked mental retardation, neurological and neoplastic diseases, pointing to the
wide ranging involvement of miRNAs in disease.
Methods and Findings: To explore the role of miRNAs in schizophrenia, 59 microRNA genes on the X-chromosome were
amplified and sequenced in males with (193) and without (191) schizophrenia spectrum disorders to test the hypothesis
that ultra-rare mutations in microRNA collectively contribute to the risk of schizophrenia. Here we provide the first
association of microRNA gene dysfunction with schizophrenia. Eight ultra-rare variants in the precursor or mature miRNA
were identified in eight distinct miRNA genes in 4% of analyzed males with schizophrenia. One ultra-rare variant was
identified in a control sample (with a history of depression) (8/193 versus 1/191, p=0.02 by one-sided Fisher’s exact test,
odds ratio=8.2). These variants were not found in an additional 7,197 control X-chromosomes.
Conclusions: Functional analyses of ectopically expressed copies of the variant miRNA precursors demonstrate loss of
function, gain of function or altered expression levels. While confirmation is required, this study suggests that microRNA
mutations can contribute to schizophrenia.
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Introduction
Schizophrenia typically presents in early adulthood or late
adolescence. Men have an earlier age of onset than women, and
also tend to experience a more serious form of the illness with
more negative symptoms, poorer chances of a full recovery, and a
generally worse outcome [1]. Systematic reviews indicate that
schizophrenia seems more common in men than in women (risk
ratio of above 1.4:1).
MicroRNAs (miRNAs) are a large family of small, non-coding
RNAs that negatively regulate gene expression at the post-
transcriptional level [2–4]. In animals, miRNAs bind to comple-
mentary sites in target mRNAs, generally at 39 untranslated
regions (UTRs), to create imperfectly paired miRNA/mRNA
heteroduplexes that inhibit translation or increase degradation of
target mRNAs.
MiRNA genes are scattered among all the chromosomes in
humans, except for the Y- chromosome. Most miRNAs are Pol II
transcripts with a 59 Cap and 39 Poly(A) tail termed primary
miRNA (pri-miRNA) [5]. The pri-miRNAs are processed to hair-
pin like structures termed precursor miRNA (pre-miRNA). The
terminal loop of the pre-miRNAs are cleaved to generate
miRNA/miRNA* partial duplex structures. One of the strands
is then preferentially loaded in miRNA induced silence complex
(RISC). Mature miRNAs often target 39UTRs and reduce protein
expression. Translational suppression and mRNA degradation,
modes by which mammalian miRNAs regulate gene expression,
do not require complete complementarity between the miRNA
and target. Watson-Crick base pairing between seven consecutive
nucleotides in the target mRNA’s and nucleotides 2–8 (the ‘‘seed
sequence’’) at the miRNA’s 59 end is generally sufficient. For the
majority of miRNA/target combinations, the seed sequence
complementarity is a pre-requisite, although there are some
exceptions which complicate target site predictions. For most
miRNA/target combinations, a single nucleotide change in the
seed sequence or a mutation in the miRNA or precursor affecting
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6121the Drosha/DGCR8 or Dicer/TRBP processing step can result in
altered function or creation of a novel miRNA [6–9].
It is estimated that approximately one-third of human protein
coding genes are post-transcriptionally controlled by miRNAs
(reviewed in [10]). Many microRNAs are conserved in sequence
and function between distantly related organisms [11].
miRNAs regulate various biological functions including devel-
opmental timing, cell proliferation, neuronal cell fate, apoptosis
(reviewed in [12,13]), neuronal gene expression [14], brain
morphogenesis [15], muscle differentiation [16] , and stem cell
division [17]. It is speculated that condition-specific, time-specific,
and individual-specific levels of gene expression may be due to the
interactions of different miRNAs accounting for more accurate
genetic expression of various traits [18]. The large number of
miRNA genes, the diverse expression patterns and the abundance
of potential miRNA targets suggest that miRNAs may be a
significant but unrecognized source of human genetic disease,
including neuropsychiatric disorders. A sequence variant in the
binding site for the miRNA miR-189 in the SLITRK1 (MIM #
609678) mRNA has been shown to be associated with Tourette
syndrome [19]. However, two recent studies of ,800 and ,2300
Tourette syndrome patients and family members found non-
transmission of the variant in two families in each study from
parent to affected child [20,21] the former study suggested that the
variant may be a rare Ashkenazi Jewish population variant. In
addition, components required for miRNA processing and/or
function have also been implicated in fragile X mental retardation
[22], chromosome 22q11 deletion syndrome (DiGeorge syndrome)
[23,24] and cancer [25], pointing to the wide ranging involvement
of miRNAs in disease.
To explore the possibility that high risk structural variants in the
microRNA genes could predispose to schizophrenia, we chose the
X-chromosomal miRNA genes available at the time of the study.
59 microRNA genes on the X-chromosome were sequenced in
193 unrelated male patients with schizophrenia and 191 male
controls. The one tested hypothesis is that ultra-rare variants in the
X-linked microRNAs predispose to schizophrenia, consistent with
reduced fertility in schizophrenia and consequent elimination of
high risk X-linked mutations within a few generations [26]. This
analysis should be distinguished from linkage disequilibrium/Hap
Map analyses in which thousands of hypotheses are typically being
tested.
Materials and Methods
Samples
All 193 male Caucasian schizophrenic patients met criteria for
the disease as defined by the Diagnostic and Statistical Manual,
Fourth Edition, Revised (DSM-IV-R), as described previously
[27]. In brief, schizophrenic patients were ascertained from a
variety of inpatient and outpatient centers in south Minnesota.
These included two state hospitals, two tertiary care hospitals, and
two outpatient mental health centers. Institutional review board
approval for studies with human subjects was granted by each
participating institution, including the Institutional Review Board
of the City of Hope, IRB#99065, and all participants signed
informed consent statements. All cases were diagnosed by a
research psychiatrist based on Diagnostic and Statistical Manual,
Fourth Edition, Revised (DSM-III-R) criteria. Strict fulfillment of
the diagnostic criteria was assessed primarily through the review of
medical records. The southern Minnesota region has a limited
number of psychiatric and medical care sources and multiple
medical records covering the course of entire illness were often
available. The male controls were Midwest Caucasians with no
known history of diagnosed psychiatric illness.
PCR Amplification and sequencing
The genomic sequence and adjacent flanking sequences of the
precursors of 59 X-linked microRNA genes (miRBase 10.1,
http://microrna.sanger.ac.uk/sequences/) were amplified and
sequenced with the ABI model 3730 sequencer. The miRNA
accession numbers and primer sequences are listed in Table S1.
The nucleotide alterations were analyzed with Sequencher
software
TM (Gene Codes, Ann Arbor, MI). Mutations were
confirmed by reamplifying from genomic DNA and sequencing
in the opposite direction.
Gene pool analysis
A gene pool analysis [28] was performed to identify the private
mutations from high risk X-chromosomal variants that predispose
to schizophrenia, which is associated with reduction in offspring.
The high risk alleles are ultra-rare, i.e. not expected even once in
the gene pool analysis. Less than 1 per 250,000 controls (1 per
500,000 control alleles) is expected to have the mutation at
random if: i) 1% or less of the population has schizophrenia; ii) 2%
of these patients have high risk X-linked miRNA mutations
expected to impart lower reproductive fitness (especially before the
development of effective drug therapy); and iii) the eight ultra-rare
variants found in schizophrenia constitute less than 2% percent of
the total miRNA mutations. Thus, such variants are not expected
in 7,197 control X-chromosomal alleles.
Control individuals (10,000 autosomal alleles, 7197 X chromo-
some alleles and 2803 Y chromosome alleles) were ascertained
from a Midwest population-based sample from Minnesota and a
more ethnically and geographically diverse sample of hemophilia
families. The total ethnicity distribution is as follows: 86.8%
European Caucasians, 4.3% Hispanics, 2.2% Asians, 2% Blacks,
2% Mestiza Columbian, 0.8% American-Indians and 1.9% of
unknown ethnicity. The average age of the individuals included in
the gene pool is 44 years, so most of these individuals would have
manifested schizophrenia if that were their destiny. To our
knowledge there is no relationship between hemophilia and
schizophrenia; none of the patients with hemophilia are known to
have schizophrenia.
The concentration of individual DNA samples was estimated by
both UV spectrophotometry and agarose gel electrophoresis with
diluted quantitation standards. Samples were diluted to 200 ng/ml
and combined into pools of 10, 30 and 100 samples. The
concentration of each sample per ml in the pool is 20 ng, 6.7 ng
and 2 ng, respectively.
Allele-specific amplification assays were developed for each case
or control cohort-specific variant [29–31]. The specificity and
selectivity of each assay were determined utilizing negative and
positive controls spiked within gene pool samples. As previously
described, the sensitivity of the allele-specific PCR assay must be at
least four-fold greater than the number of pooled alleles in the
sample, i.e. for autosomal genes, a 30-in-one sample pool contains
60 alleles. Thus, spikes within 30-in-one pools must be able to
detect signal when the allele is present at one part in 240. For pools
of 100 in 1, an allele must be detected with a sensitivity of at least
one part in 800. Allele-specific PCR is optimized in the manner
previously shown to produce specificity for 69 consecutive assays
[30]. To facilitate timely optimization, eight oligonucleotides are
routinely generated: i) Two allele-specific downstream oligonucle-
otides utilizing the 39 nucleotide for allele specificity and differing
in length (Wallace temperature [4u6(G+C)+2u6(A+T)] of about
46/48 or 50/52 degrees, respectively) were paired with either of
Schizophrenia/miRNA Alteration
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250 bp and ii) two upstream allele-specific oligonucleotides
utilizing the 39 nucleotide for allele specificity (Wallace temper-
atures 46/48 or 50/52 degrees) are generated and paired with
either of two generic downstream oligonucleotides to form
amplicons of about 150–250 bp. After an initial optimization for
oligonucleotide concentration and magnesium concentration, an
allele-specific reaction with the required sensitivity is used for the
gene pool assay. If none achieve the required sensitivity, further
optimization is performed as previously described [30]. The assay
conditions for each of the ultra-rare assays are as described (Table
S2).
Cell lines and plasmids
HEK293, Hela, NIH-3T3 cells were purchased from ATCC
and maintained in high glucose (4.5 g/l) DMEM supplemented
with 2 mM glutamine, 10% FBS, and 2 mM Penicillin/Strepto-
mycin. Transfections to HEK293, NIH-3T3 and Hela cells were
performed with Lipofectamine 2000 (Invitrogen) in duplicate in
24-well plate formats when cells are at 70–80% confluency.
Cell based miRNA processing test
Primary miRNA (pri-miRNA) expression plasmids and report-
ers bearing either fully complementary or seed sequence
complements to the miRNAs were co-transfected into HEK293
cells. Dual-reporters (expressing both Firefly and Renilla lucifer-
ase) carrying the miRNA fully complementary sequences (si
reporter) in the 39 UTR of the Renilla transcript were used to
validate the ability of cloned pri-miRNA expression plasmids to
produce functional, mature miRNAs. Dual-reporters carrying the
partially complementary sequence (mi reporter: mis-matched at
position 11 to 13 and the last two nts in miRNA/mRNA duplex)
of a miRNA in the 39UTR of Renilla were used to measure the
strength of translational repression from the corresponding
miRNA.
In order to express the pri-miRNAs, we retrieved the stem-loop
sequences from miRBase 10. The stem-loop sequence plus
flanking sequences extending over 100 bases in both directions,
was PCR amplified from genomic DNA. A miRNA expression
vector was constructed by first cloning the human Pol II U1
promoter upstream of a multiple cloning site in the Bluescript SK
plasmid to create SK-U1. Secondly, the U1 transcriptional
termination sequence was cloned downstream of the MCS of
SK-U1 to create the fU1-miR miRNA expression vector. The
primary miRNA was cloned into the Xho I and BamH1 sites of
fU1-miR. miRNA variants were cloned in the same manner as the
wild type miRNAs from patient DNA when available. If samples
were no longer available, the QuikChange II site-directed
mutagenesis kit was used to create mutants within the wildtype
expression constructs. All clones were sequenced to confirm the
normal miRNA and mutant forms.
For si reporters, all miRNAs and their homologous mutant
target sequences were designed as fully complementary to the
mature miRNA sequence. The oligonucleotides for the two
strands were inserted into the psiCHECK Xho I/Spe I or
XhoI/Not I digested reporter 39 UTR of the Renilla luciferase
gene. All target clones were verified by sequencing. For miRNA
reporters, all the inserted sequences in the reporter 39 UTR of the
Renilla luciferase gene were designed with bulges at positions 11 to
13 and were unpaired for two nucleotides at the 39 end of the
miRNA.
About 1610 ˆ5 HEK293 cells per well in 500 microliters of
growth media were plated in 24-well plates one day prior to
transfection. The cells were at 70–80% confluency at the time of
transfection. Each well was transfected with 5 ng reporter, 100 ng
miRNA expression constructs (1:20 ratio, 1:5 ratio was used if the
knockdown of the si target was .95%: 25 ng of miRNA
expression plasmid and 75 ng stuffer Blue-script SK) and 1 ul
Lipofectomine 2000. Forty eight hours post transfection, the cells
were lysed with 100 ml Passive lysis buffer (Promega) and luciferase
levels were analyzed from 20 ml lysates using the Dual Luciferase
reporter assay (50 ml of each substrate reagent, Promega) on a
Veritas Microplate Luminometer (Turner Biosystems). Changes in
expression of Renilla luciferase (target) were calculated relative to
Firefly luciferase (internal control) and normalized to the miRNA
expression vector control fU1-miR.
Point mutations were created with the QuikChange site-
directed mutagenesis kit II (Stratagene) following the protocol
included in the kit. Mutations were confirmed by sequencing.
Northern blot
Two different transfections were performed in HEK 293 cells to
detect processing of expressed pri-miRNA in vivo. One transfec-
tion contained pri-miRNA expression constructs alone, while the
Table 1. Ultra-rare miRNA cohort-specific variants.
ID# Disease miRNA Variant in mature miRNA Variant in precursor Gene pool
S358 Schizophrenia let-7f-2 11 G.A 0/7,197
S418 Schizophrenia miR-18b 32 A.G 0/7,197
S590 Schizophrenia miR-505 8 C.T 0/7,197
S356 Schizophrenia miR-502 13 C.G 1/7,197
a
S014 Schizophrenia miR-188 7 C.T (188-3p) 0/7,197
MC179 Psychosis miR-325 8 G.A (325-3p)
b 0/7,197
S711 Schizophrenia miR-660 15 C.T 0/7,197
S596 Schizophrenia miR-509-3 13 C.T (509-3p) 0/7,197
MC149 Control
c miR-510 4 T.C (510-3p) 0/7,197
aOne individual in the initial gene pool sample had the variant, but was excluded from the sample when a history of depression was found on review of the medical
records. The extent of the depression requires further clarification.
bThe exact sequence for the mature 3p is not known; the numbering is based on the predicted sequence.
cThirty-four years of medical history until death included depression, gout, closed angle glaucoma, tricuspid and aortic insufficiency, congestive heart failure, and mitral
aortic prosthesis.
doi:10.1371/journal.pone.0006121.t001
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Northern blots were performed with RNAs from both transfec-
tions. U2 was used as the RNA loading control and co-transfected
siRNA-1 that target HIV Tat/Rev was used as the transfection
control. Northern blots were performed according to a previous
publication [32]. Briefly, 20 mg total RNA was loaded on a 12.5%
SDS-PAGE gel. Gels were transferred to a Hybond-N+ (Amer-
sham Pharmacia biotech, positive charged) membrane. DNA
probes were used for all Northern blots. Hybridizations were
carried out in PerfectHyb
TM Plus hybridization buffer (Sigma) for
16 hours (Table S3).
Statistical Considerations. The hypothesis considered here
is that ultra-rare, essentially private, mutations in the X-linked
miRNA are collectively associated with schizophrenia. This
hypothesis, or any hypothesis about a collection of mutations,
admits the possibility of including mutations with a wide range of
penetrance. Because the phenotype has likely been subject to a
substantial selective pressure, the set of rare alleles is likely to
include more genes of high penetrance, and fewer neutral genes,
compared to more frequent alleles, all else being equally likely. A
total of 384 X-linked alleles of the miRNA genes were sequenced
in order to discover multiple rare alleles. Mutation discovery was
necessary in controls as well as cases, in order to distinguish a
substantial risk attributable to rare alleles collectively from a high
frequency of neutral mutations. Restricting attention to mutations
detected only once in the sequencing effort would provide a
measure of rarity, but an additional requirement that the variants
be absent from a pool of 7,197 X chromosomal alleles served to
further exclude low-frequency neutral alleles in favor of essentially
private mutations. Because variants were ascertained by
sequencing, the frequency with which the variants were detected
in the pooled alleles cannot serve as a reference for statistical
comparison. After defining ultra-rare variants to be those detected
only in either sequenced cases or sequenced controls and not in the
gene pool control alleles interrogated, the primary analysis is
simply a comparison of the number of ultra-rare alleles among 193
cases to the number among 191 controls, using Fisher’s exact test
(StatXact, CYTEL, Cambridge, MA). We regard an unadjusted,
one-sided significance probability (p-value) as relevant to the
testing of this single hypothesis. The confidence interval of the
estimate for attributable risk is a binomial confidence interval
calculated by the ‘‘Blyth-Still-Casella’’ method in StatXact.
Results
Eight variants in the precursor or mature miRNA were
identified in eight distinct miRNA genes in males with schizo-
phrenia and one ultra-rare variant was identified in a control
sample (with a history of depression) (8/193 versus 1/191,
p=0.019, Fisher’s exact test) (Table 1). These variants are ultra-
rare, as determined by gene pool analyses of an additional 7,197
control X-chromosomes (Materials and Methods). Each ultra-rare
variant was present in a different individual.
Five cohort-specific variants, one in a patient and four in
controls, were found in the gene pool analyses at a frequency
greater than 0.02% (p=0.21, Fisher’s exact test) (Table 2). Five
common variants in miRNA precursors were found in both
patients and controls with similar frequencies (Table S4).
To assess the functional consequences of the point mutations,
pri-miRNAs and mutant versions of each miRNA were co-
transfected with their corresponding siRNA (si) and miRNA (mi)
targets (see Materials and Methods). Three or more transfections
were performed, with duplicates in each transfection. Five of the
variants identified in patients, as well as one identified in a control
sample (with depression), contained a point mutation in the
mature coding region (miRNA let-7f-2, miR-188, miR-325, miR-
660, miR-509-3, and miR510) (Figures 1, 2 and Figs. S1, S2, S3;
S5). These novel, ultra-rare variants in the mature miRNAs were
predicted to have altered target specificity and perhaps new
endogenous targets. The results of the in vitro functional assays for
the nine variants are described below. (In all pictures: the mature
sequences in the stem-loop structure are in uppercase except SNPs
in mature sequence are in lower case; sequences outside the
mature sequences are in lower case except SNPs outside the
mature sequences are in uppercase.)
Let-7f-2: 11 G.A
This variant was identified in the mature miRNA at position 11
(Fig. 1). In the functional assays, the wild type let-7f-2 knocks down
expression of its complementary ‘si’-mutant target; the mutant
miRNA is much less effective in knockdown of the wild type target.
On the other hand, the mutant miRNA strongly down-regulates its
complementary ‘si’- mutant target, while the wild type miRNA has
about the same knockdown of the mutant and wild type targets.
miR-188: 7 C.T (3p)
This variant occurs within the seed sequence at the 7th
nucleotide of the mature miR-188-3p (Fig. 2). In our assay system,
the effect of the 5p variant is not dramatic. The 3p variant is less
effective than the wild type 3p in suppressing expression of the ‘si’
target, although there is no difference with the ‘mi’ target. With
the mutant ‘si’ target, the knock-down by the variant miRNA is
enhanced compared to the wild type miRNA. In addition to the
functional tests shown herein, this variant in the seed sequence
could potentially affect the expression of new target sequences with
a sequence matched to the variant.
miR-18b/18b*: 32 A.G
This variant occurs at the 4th nt following the last base of the
mature sequence in the terminal loop close to the Dicer/TRBP
processing site (Fig. 3). The mutant miRNA has decreased activity
Table 2. miRNA cohort-specific sequence variants found in the gene pool analyses.
ID# Disease miRNA Variant in mature miRNA Variant in precursorGene pool
S464 Schizophrenia miR-509-3 22 G.A (509-3-5p) 2/7,197
MC527 Control miR-509-3 19 C.G (509-3-5p) 10/4,962
MC333 Control miR-421 73 G.A 16/4,962
MC40 Control miR-934 1 T.G 4/7,197
MC93 Control miR-450-2 4 T.C 8/4,962
doi:10.1371/journal.pone.0006121.t002
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target’ assays. The 18b* strand also has reduced activity compared
to wild type in the mutant-‘si target’ assay, although there is
essentially no difference between wild type and mutant in the
mutant-‘mi target’ assay.
miR-502: 13 C.G
This variant is of interest, as it occurs in the precursor miRNA
at 3 nucleotides before the Drosha/DGCR-8 processing site
(Figure 4). The mutation should produce a bulge, which will
change the structure of the stem of the precursor miRNA, and will
likely affect the site of Drosha cleavage in producing pre-miR-502.
As expected, both the 5p and 3p products are affected: 5p slightly
reduces the ‘si’ and ‘mi’ functions, while 3p slightly reduces the ‘si’
function. A Northern blot also shows a decreased level of both the
5p and 3p mature miRNA strands (Figure 5).
miR-510: 4 T.C (3p)
This variant, which was detected in a control sample, occurs in
the seed sequence at the 4
th nucleotide of the predicted miR-510-
3p (Fig. S1). The mutant miRNA (both the 5p and the 3p strands)
has much less activity than the wild type in the knock-down of ‘si’
expression; the 5p mutant strand (but not the 3p) also is less active
in suppressing ‘mi’ expression. This mutation most likely affects
the structure of the pre-miR-510, as it affects the function of
mature miR-510 on both strands. The Northern blot shows that
both the 5p and 3p products are reduced (Fig. S1a and S1b).
miR-660: 15 C.T
This variant occurs at the 15th position of the mature miR-660-
5p, but it is not in the seed sequence (Fig. S2). The functional data
show that both the variant and wild type miRNAs are equally
strong suppressors of both the 5p ‘si’ and ‘mi’ target sequences.
Figure 1. Function test of let-7f-2-G/A. A single base substitution G.A was identified in the mature miRNA of let-7f-2 at position 11. To examine
the possible functional consequences of this mutation, the wild type and mutant variants were tested against its corresponding ‘si’ and ‘mi’ target
sequence. The results obtained with these analyses demonstrate that the mutant sequence can downregulate its own fully complementary ‘si’
sequence (bar #6), but its knockdown of the let-7f ‘si’ sequence was dramatically reduced (bar #3). On the other hand, the let-7f knockdown of the
mutant ‘si-target’ remained unperturbed (bar #5). These results demonstrate that the mutant produces a stronger siRNA phenotype than the wild
type miRNA with the cognate complementary targets. On the other hand, the variant elicits a weaker miRNA phenotype than the wild type. Sic-
[target]-Si and Sic-[target]-Mi: Dual reporters containing the miRNA target sequences (Si, fully complementary; Mi, partially complementary) in the
39UTR of the Renilla luciferase gene (for details, see Materials and Methods). fU1-miR-[miRNA] and fU1-miR-[miRNA]-m: miRNA expression vectors
containing the primary sequence of a specific miRNA gene (wild type and mutant, respectively) (for details, see Materials and Methods). fU1-miR:
Expression vector alone without the miRNA gene inserted.
doi:10.1371/journal.pone.0006121.g001
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the wild type miRNA, which has no effect on 3p ‘si’ function. In
addition to the functional tests herein, the base change could affect
the natural targeting functions of the miRNA since this position
affects the 39end base pairing of miRNA/mRNA.
mir-325: 8 G.A (3p)
This variant occurs at the 8
th position of the mature miR-325-
3p strand (Fig. S3). The functional assays are indeterminate:
neither the wild type nor mutant miRNA generated knockdowns
of the wild type ‘si’ or ‘mi’ targets. At this time, there is no
information concerning whether or not miR-325* (3p) is
functional. This miRNA was originally cloned in a murine system
and therefore there is no data demonstrating that the human
homologue can be expressed and processed in HEK293 cells. We
also analyzed processing of this miRNA in Hela and NIH 3T3
cells, and in both cases were unable to detect knockdown of the
complementary target. It is also possible that this miRNA may be
processed through an alternative miRNA pathway [33,34].
miR-505: 8 C.T
This variant occurs at the 8
th nucleotide of the precursor
miRNA and is distal to both the Drosha and Dicer cleavage sites
(Fig. S4). Functional testing of the mutant shows essentially no
difference between the mutant and wild type miRNAs for both the
‘si’ and ‘mi’ targets.
miR-509-3: 13 C.T (3p)
This variant is in the mature miR-509-3p at position 13, but it is
not in the seed sequence (Fig. S5). There is essentially no difference
in the mutant and wild type miRNAs with respect to ‘si’ or ‘mi’
function and none would be predicted from the position of the
Figure 2. Function test of miR-188-5p/3p. Variant miR-188-5p/3p-m has a ‘C’ to ‘T’ (U) transition at the 7th nt of the mature miR-188-3p within
the seed sequence. This variant results in a change of G:C to G:U pairing in the seed sequence. In our assay system, the effect of the variant is not
dramatic. Nevertheless, this variant will create a seed sequence where this position can pair with an A, thus potentially affecting the expression of
new target sequences with a matched seed sequence. Sic-[target]-Si and Sic-[target]-Mi: Dual reporters containing the miRNA target sequences (Si,
fully complementary; Mi, partially complementary) in the 39UTR of the Renilla luciferase gene (for details, see Materials and Methods). fU1-miR-
[miRNA] and fU1-miR-[miRNA]-m: miRNA expression vectors containing the primary sequence of a specific miRNA gene (wild type and mutant,
respectively) (for details, see Materials and Methods). fU1-miR: Expression vector alone without the miRNA gene inserted.
doi:10.1371/journal.pone.0006121.g002
Schizophrenia/miRNA Alteration
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unknown whether the target specificity will be changed. It is
possible that the base change could affect the regulation of
endogenous targets, as the 13
th position is important for 39 end
base pairing.
Discussion
We chose to examine hemizygous miRNA on the X-
chromosome in males so that the full phenotypic consequences
of a variant could be assessed without the possible mitigating
effects of a wild-type allele.
The assessment of statistical significance is based on a single test
of the collective effect of all microRNAs on the X-chromosome.
This is similar to the strategy of Walsh et al. who tested the
collective effect of individually rare copy number variants on the
risk of schizophrenia [35]. The estimated odds ratio of 8.2,
combined with the 1% lifetime incidence of schizophrenia, implies
an estimated risk of 7.9% among individuals harboring a rare
mutation, i.e. an estimated relative risk (RR) of 7.9 (95% CI 1.34–
300). This is consistent with the finding that most of the rare
mutations detected had a likely impact on regulatory function. The
estimated overall attributable risk of the X-linked miRNAs is 0.036.
Functional analyses indicated that some of these variants display
altered regulatory function consistent with dominant inheritance. If
similar risk levels apply to the 90% of microRNAs on autosomes,
with half of the variants having dominant effects, then the risk
attributable to rare microRNA mutations would be approximately
20%.Thisis,ofcourse,averyroughestimate,butthe dataimplicate
microRNA mutations in schizophrenia, and suggest that their
contribution to disease etiology may be substantial.
The altered functions or defects in processing of the pre-
miRNAs in the mutant alleles detected in our analyses suggest that
these microRNAs may contribute to the development of
schizophrenia. It is important to note that each microRNA can
potentially regulate dozens, and perhaps even hundreds of
different transcripts during development, so even subtle defects
in activity can have profound effects on development of the
nervous system.
Identified targets of the miRNAs in which ultra-rare variants
were found are listed in Table S5. Such targets include neuregulin
Figure 3. Function test of miR-18b-A/G. Variant miR-18b/18b*-m has an ‘A’ to ‘G’ mutation at the 4th nt following the last base of the mature
sequence, which is also in the predicted terminal loop structure. This sequence difference may affect processing and/or stability as there is a
reduction in the level of target knockdown activity when compared to wild type in the ‘si-target’ (bar #2v s#3) and the ‘mi-target’ assays (bar #5v s
#6). In contrast, the function of the miR-18* strand does not appear to be affected by this mutation (bar#8 vs 9 and Bar #11 vs 12). Sic-[target]-Si
and Sic-[target]-Mi: Dual reporters containing the miRNA target sequences (Si, fully complementary; Mi, partially complementary) in the 39UTR of the
Renilla luciferase gene (for details, see Materials and Methods). fU1-miR-[miRNA] and fU1-miR-[miRNA]-m: miRNA expression vectors containing the
primary sequence of a specific miRNA gene (wild type and mutant, respectively) (for details, see Materials and Methods). fU1-miR: Expression vector
alone without the miRNA gene inserted.
doi:10.1371/journal.pone.0006121.g003
Schizophrenia/miRNA Alteration
PLoS ONE | www.plosone.org 7 July 2009 | Volume 4 | Issue 7 | e61211 (NGR1), Disrupted in schizophrenia 1 (DISC1) and Regulator of
G-protein signaling 4 (RGS4). These genes have been frequently
studied and are commonly considered the best candidate genes for
schizophrenia [36]. Defects in miRNAs altering the interactions
between miRNAs and their mRNA targets may contribute to
schizophrenia.
Six of the nine ultra-rare variants occur in the miRNA mature
sequence (Table 1): Since miRNAs rely on base-pairing for their
function, especially the ‘seed’ sequence base pairing, these
variants are expected to have different regulatory specificities.
All variants that occur in the mature miRNA sequence are
expected to have altered function because the target spectra are
changed. However only two of the variants in the mature
miRNA sequences exhibit a strong alteration in the in vitro
functional assays that measure a subset of miRNA function; the
in vitro function in two other variants with alterations in the pre-
miRNA is also affected.
In summary, these studies represent the first statistically
significant association between microRNA mutant alleles and
schizophrenia. The absence of variants in 7,197 and additional
control X-chromosomes and abnormal functional studies support
an etiological link. Future studies will be required to confirm the
association and to determine whether autosomal miRNAs are also
implicated in disease. The dominant phenotype suggested by some
of the functional analyses herein is consistent with autosomal
dominant as well as autosomal recessive inheritance of predispo-
sition to schizophrenia. The extrapolation from our data to
possibly 20% of schizophrenia resulting from miRNA mutations
involves multiple caveats, including: i) replication of the X-
chromosomal association and behavioral studies of mouse knock-
ins are important to verify both the association and the
attributable risk for X-chromosomal miRNA mutations; ii) there
are major uncertainties in the estimate of miRNA causing
schizophrenia by a dominant mechanism and iii) there are no
Figure 4. Function test of miR-502-C/G. Variant miR-502-5p/3p-m has a ‘C’ to ‘G’ transversion at the 3
rd nt upstream of the mature miR-502-5p
sequence. This mutation will produce a bulge which changes the structure of the stem of the precursor miRNA. Most likely, this structural change will
affect the site of Drosha cleavage in producing pre-miR-502; therefore, both the 5p and 3p products should be affected. Reduced target knockdowns
were observed in transfection assays (bar #2v s3 ,# 5 vs 6 and # 8 vs 9). Sic-[target]-Si and Sic-[target]-Mi: Dual reporters containing the miRNA
target sequences (Si, fully complementary; Mi, partially complementary) in the 39UTR of the Renilla luciferase gene (for details, see Materials and
Methods). fU1-miR-[miRNA] and fU1-miR-[miRNA]-m: miRNA expression vectors containing the primary sequence of a specific miRNA gene (wild type
and mutant, respectively) (for details, see Materials and Methods). fU1-miR: Expression vector alone without the miRNA gene inserted.
doi:10.1371/journal.pone.0006121.g004
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variants that predispose to schizophrenia.
At least two important clinical implications arise. The clinical
utility of these observations depend on a much larger sample size
to identify the relative risk with greater certainty. If our point
estimate of relative risk is correct, patients with these variants will
have about an 8% risk of schizophrenia which may be of clinical
utility in certain families that have experienced the utter
devastation that this disease can bring. The clinical utility increases
as the relative risk increases. Our data are consistent with a higher
relative risk if the miRNA gene with the ultra-rare variant found in
the control were found to be involved in diseases other than
schizophrenia. In addition, as gene interactions become apparent,
relative risk calculations may be refined. Finally, chemically
synthesized miRNA analogs with stability within cells may have
preventative or therapeutic implications for affected families [37–
39].
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0006121.s001 (0.06 MB
XLS)
Table S2
Found at: doi:10.1371/journal.pone.0006121.s002 (0.03 MB
XLS)
Table S3
Found at: doi:10.1371/journal.pone.0006121.s003 (0.05 MB
XLS)
Table S4
Found at: doi:10.1371/journal.pone.0006121.s004 (0.02 MB
XLS)
Table S5
Found at: doi:10.1371/journal.pone.0006121.s005 (0.04 MB
DOC)
Figure S1 In all pictures: the mature sequences in the stem-loop
structure are in uppercase except SNPs in mature sequence are in
lower case; sequences outside the mature sequences are in lower
case except SNPs outside the mature sequences are in uppercase.
Fig. S1a: Function test of miR-510-T/C Variant miR-510-T/C
has a ‘T’ (U) to ‘C’ transition in the seed of the predicted miR-
510* (3p). Transfection assays show processing of the miR-510-3p
product and its ability to knockdown the corresponding ‘si’ target
sequence (bar# 8). The ‘T’ (U)/‘C’ mutation produces a pre-miR-
Figure 5. Northern blot results of miR-502-C/G. The impaired functional activity of the variant miR-502-C/G was supported by Northern blot
analyses, as the production of pre-miR-502 and mature 502-5p/3p were both reduced. Top is the result of the blot that was hybridized with miR-502
3p probe; middle is the result of the blot that was hybridized with the 5p probe; bottom is the result of the blot that was hybridized with U2 snoRNA
probe and spike-in siRNA probe. U2 was used as RNA sample loading control. SiRNA-1 that targets HIV Tat/Rev was used as a transfection control.
Lanes 1, 3, 5, and 6 are miR-502; Lanes 2, 4, 8, and 9 are transfected with the variant. Lane 7 is the expression vector alone: fU1-miR.
doi:10.1371/journal.pone.0006121.g005
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PLoS ONE | www.plosone.org 9 July 2009 | Volume 4 | Issue 7 | e6121510 with much less activity (Bar # 2 vs3, bar #5 vs 6 and bar #8
vs 9). This mutation most likely affects the structure of the pre-
miR-510, as it affects the function of mature miR-510 on both
strands. Sic-[target]-Si and Sic-[target]-Mi: Dual reporters con-
taining the miRNA target sequences (Si, fully complementary; Mi,
partially complementary) in the 39UTR of the Renilla luciferase
gene (for details, see Materials and Methods). fU1-miR-[miRNA]
and fU1-miR-[miRNA]-m: miRNA expression vectors containing
the primary sequence of a specific miRNA gene (wild type and
mutant, respectively) (for details, see Materials and Methods). fU1-
miR: Expression vector alone without the miRNA gene inserted.
Fig. S1b: Northern blot test of miR-510-T/C Northern blot
analyses confirmed that the production of both pre-miR-510 and
miR-510-5p/3p were reduced. Top is the result of the blot that
was hybridized with miR-510 3p probe; middle is the result that
the blot was hybridized with 5p probe; bottom is the result that the
blot was hybridized with U2 snoRNA probe and spike-in siRNA
probe. U2 was used as RNA sample loading control. SiRNA-1
that target HIV Tat/Rev was used as transfection control. Lanes
1, 2, and 3 are miR-510; Lanes 4 and 5 are transfected with the
variant.
Found at: doi:10.1371/journal.pone.0006121.s006 (0.49 MB
DOC)
Figure S2 Function test of miR-660-C/T Variant miR-660 has
a ‘C’ to ‘T’ (U) transition at the 15th position of the mature
miRNA. The functional assay data shows it has little effect on the
processing of the miRNA. The base change could affect the
natural targeting functions of the miRNA since this position affects
the 39end base pairing of miRNA/mRNA. Sic-[target]-Si and Sic-
[target]-Mi: Dual reporters containing the miRNA target
sequences (Si, fully complementary; Mi, partially complementary)
in the 39UTR of the Renilla luciferase gene (for details, see
Materials and Methods). fU1-miR-[miRNA] and fU1-miR-
[miRNA]-m: miRNA expression vectors containing the primary
sequence of a specific miRNA gene (wild type and mutant,
respectively) (for details, see Materials and Methods). fU1-miR:
Expression vector alone without the miRNA gene inserted.
Found at: doi:10.1371/journal.pone.0006121.s007 (0.03 MB
DOC)
Figure S3 Function test of miR-325-G/A Variant miR-325-G/
A occurs on the miR-325-3p strand. At this time, there is no
information concerning whether or not miR-325* (3p) is
functional. Interestingly, our functional assays with the wild type
and mutant variants did not generate knockdowns of the ‘si’ target.
This miRNA was originally cloned in a murine system and
therefore there is no data demonstrating that the human
homologue can be expressed and processed in HEK293 cells.
(We also analyzed processing of this miRNA in Hela and NIH
3T3 cells, and in both cases were unable to detect knockdown of
the complementary target). Sic-[target]-Si and Sic-[target]-Mi:
Dual reporters containing the miRNA target sequences (Si, fully
complementary; Mi, partially complementary) in the 39UTR of
the Renilla luciferase gene (for details, see Materials and Methods).
fU1-miR-[miRNA] and fU1-miR-[miRNA]-m: miRNA expres-
sion vectors containing the primary sequence of a specific miRNA
gene (wild type and mutant, respectively) (for details, see Materials
and Methods). fU1-miR: Expression vector alone without the
miRNA gene inserted.
Found at: doi:10.1371/journal.pone.0006121.s008 (0.04 MB
DOC)
Figure S4 Function test of miR-505-C/T Variant miR-505/
505*-C/T has a ‘C’ to ‘T’ (U) transition at the 8th nt (relative to
the 59 end of the upper strand of the mature miR-505). This
variant is distal to both Drosha and Dicer cleavage sites.
Functional testing of this mutant revealed little difference when
compared with the wild type miRNA for both ‘si’ and ‘mi’ targets.
Sic-[target]-Si and Sic-[target]-Mi: Dual reporters containing the
miRNA target sequences (Si, fully complementary; Mi, partially
complementary) in the 39UTR of the Renilla luciferase gene (for
details, see Materials and Methods). fU1-miR-[miRNA] and fU1-
miR-[miRNA]-m: miRNA expression vectors containing the
primary sequence of a specific miRNA gene (wild type and
mutant, respectively) (for details, see Materials and Methods). fU1-
miR: Expression vector alone without the miRNA gene inserted.
Found at: doi:10.1371/journal.pone.0006121.s009 (0.05 MB
DOC)
Figure S5 Function test of miR-509-3-C/T. This miRNA
variant has a ‘C’ to ‘T’ (U) transition at the 13th nucleotide of
the mature miRNA. (Fig. S5). Our functional assays show that this
mutation has a weak effect on the processing of the mature
miRNA. This base change could affect the regulation of
endogenous targets as the 13th position is important for 39end
base pairing of miRNAs and mRNAs. Sic-[target]-Si and Sic-
[target]-Mi: Dual reporters containing the miRNA target
sequences (Si, fully complementary; Mi, partially complementary)
in the 39UTR of the Renilla luciferase gene (for details, see
Materials and Methods). fU1-miR-[miRNA] and fU1-miR-
[miRNA]-m: miRNA expression vectors containing the primary
sequence of a specific miRNA gene (wild type and mutant,
respectively) (for details, see Materials and Methods). fU1-miR:
Expression vector alone without the miRNA gene inserted.
Found at: doi:10.1371/journal.pone.0006121.s010 (0.04 MB
DOC)
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